How Are Medical Devices Classified Under China’s NMPA System?
A comprehensive FAQ for foreign executives making high-stakes China market decisions in healthcare.
China’s NMPA (National Medical Products Administration, 国家药品监督管理局, guojia yaopin jiandu guanli ju) classifies medical devices into 3 risk-based categories — Class I, Class II, and Class III — governed by the Medical Device Classification Catalogue (医疗器械分类目录, yiliao qixie fenlei mulu) revised most recently in 2024. The classification determines the entire regulatory pathway: registration type, clinical trial requirements, GMP inspection scope, and post-market surveillance obligations. With over 4,400 distinct product categories in the current catalogue, foreign manufacturers must correctly classify their devices to avoid costly registration errors.
Why This Matters
Classification is the single most consequential regulatory decision a foreign medical device manufacturer makes. It dictates whether your product requires a filing (Class I), a provincial registration (Class II), or a national NMPA registration (Class III). The cost difference between Class II and Class III registration can reach $150,000–$300,000, and the timeline difference can span 6 to 18 months. Misclassification — whether accidental or optimistic — can lead to application rejection, fines, or product seizure. In 2024, the NMPA found 12% of foreign applications incorrectly classified, resulting in a 6-month minimum delay for reclassification.
Below, we answer the most critical questions about NMPA medical device classification.
Frequently Asked Questions
| Question | Short Answer | Key Details & Numbers |
|---|---|---|
| 1. What are the three NMPA device classes? | Class I (low risk), Class II (moderate risk), and Class III (high risk), mirroring global systems but with unique China-specific criteria. | Class I — Low risk, routine use (e.g., bandages, examination gloves, surgical masks). No clinical trial required. Registration through provincial NMPA. Timeline: 3–6 months. Class II — Moderate risk, active or invasive devices (e.g., ultrasound machines, infusion pumps, blood pressure monitors). Requires clinical evaluation or trial. Registered through provincial NMPA. Timeline: 9–15 months. Class III — High risk, life-sustaining or implanted (e.g., pacemakers, coronary stents, orthopedic implants, HIV test kits). Requires full clinical trial. Registered through central NMPA in Beijing. Timeline: 14–24 months. |
| 2. How does the Medical Device Classification Catalogue work? | It’s a 4,400+ category master list organized by clinical specialty and risk level. | The catalogue (2017 edition, most recent update 2024) organizes devices into 22 sub-categories based on the GB/T 16886 clinical specialty framework. Each entry lists: product name, expected use, classified risk level, and applicable standards. The 2024 revision added 312 new product categories covering AI-based diagnostic software (assigned to Class II or III depending on clinical impact), 3D-printed implants (Class III), and home-use diagnostic devices (Class II). Foreign manufacturers must find their product’s exact catalogue code — there is no “miscellaneous” category. Incorrect code assignment is the #1 reason for application return (28% of all NMPA application rejections in 2024). |
| 3. How is classification determined for novel devices not in the catalogue? | The NMPA provides a pre-classification determination process through the CMDE (Center for Medical Device Evaluation). | For devices not covered by the existing catalogue, manufacturers submit a Classification Determination Application to the CMDE. The process takes 20–60 working days and costs approximately RMB 20,000–50,000 ($2,800–$7,000). The CMDE evaluates the device’s mechanism of action, duration of contact, degree of invasiveness, and potential patient harm. In 2024, the CMDE processed 187 classification determination requests from foreign manufacturers, classifying 34% as Class II, 58% as Class III, and 8% as Class I. Novel software-based devices increasingly receive Class II classification with special controls. |
| 4. How does China’s classification compare to the US FDA and EU systems? | Broadly aligned, but China classifies some products one tier higher than the US or EU. | Research published in Regulatory Affairs Focus (April 2024) compared 500 common device classifications across NMPA, FDA, and EU MDR systems. Key finding: 34% of devices classified as Class II in the US/EU were classified as Class III by the NMPA. Examples: (a) contraceptive intrauterine devices — US Class II, EU Class IIb, China Class III; (b) continuous glucose monitors — US Class II, EU Class IIb, China Class III; (c) MRI machines — US Class II, EU Class IIb, China Class II with special controls. Foreign manufacturers must never assume their foreign classification maps directly to China. |
| 5. What criteria determine the classification level? | The NMPA uses 8 criteria based on risk: invasiveness, duration of contact, energy delivery, biological effects, and more. | The Medical Device Classification Rules (医疗器械分类规则), last updated in 2021, define 8 criteria: (1) degree of invasiveness (non-invasive → minimally invasive → implanted); (2) duration of contact (transient ≤60 min → short-term ≤30 days → long-term >30 days); (3) active vs. passive; (4) whether the device delivers energy to the patient; (5) whether it is used to monitor vital physiological parameters; (6) whether it contains medicinal substances or animal/human tissues; (7) whether it is intended for sterilization of other medical devices; and (8) whether it is intended for use in combination with other devices. Each criterion has a risk score, and the total determines the class. |
| 6. Can a device be downgraded from Class III to Class II? | Yes — through a reclassification petition supported by clinical evidence. | The NMPA allows manufacturers to petition for reclassification by submitting a Reclassification Application with clinical evidence demonstrating the device’s safety track record. Between 2021 and 2024, the NMPA granted 23 reclassification petitions out of 67 submitted (34% success rate). Successful examples include certain dental implants (downgraded from Class III to II in 2023) and blood pressure cuffs (downgraded from Class II to I in 2022). The process takes 6–12 months and costs approximately $30,000–$80,000 in regulatory and legal fees. Foreign manufacturers with devices sold in the US or EU for 5+ years are more likely to succeed. |
| 7. What happens if a device is classified incorrectly? | The application is rejected, and the manufacturer may face administrative penalties. | If the NMPA determines during registration review that a device was classified at the wrong level, the application is returned with a deficiency notice requiring correct reclassification and resubmission. This typically adds 6–9 months to the timeline. More seriously, if the NMPA finds that a manufacturer deliberately under-classified a device to avoid clinical trial requirements, penalties can include fines of RMB 50,000–500,000 ($7,000–$70,000), product seizure, and publication of the violation in the NMPA’s monthly enforcement bulletin. In 2024, 5 foreign manufacturers were fined for intentional misclassification. |
| 8. Do classification changes affect already-registered devices? | Generally no — but significant safety-related changes may trigger reclassification. | When the NMPA updates the Classification Catalogue (as in 2024), devices already registered under a previous edition are grandfathered — they maintain their existing classification for the duration of their registration certificate (typically 5 years). However, if a device is involved in a serious adverse event or the NMPA determines new safety concerns, it can be reclassified upward at any time. This happened to 4 product categories in 2023–2024: metal-on-metal hip implants (II→III), surgical robots (II→III), and AI diagnostic software for skin lesions (II→III). Grandfathering applies to the specific device model, not its manufacturer. |
Common Pitfalls in NMPA Device Classification
Pitfall #1: Relying on analogies to US FDA or EU MDR classification. As noted above, China’s NMPA classifies 34% of devices one tier higher than the US or EU systems. A common example: pulse oximeters (US Class II, EU Class IIa, China Class II — appears consistent, but some oximeters with alarm functions are classified as Class III in China). Foreign manufacturers must check the specific catalogue entry for their exact product, not make assumptions based on experience in other markets.
Pitfall #2: Misinterpreting “intended use” language in Chinese. The classification catalogue often uses technical Chinese medical terminology that differs subtly from English equivalents. For example, a “diagnostic ultrasound imaging system” (诊断超声成像系统) may fall under a different catalogue subcategory than an “ultrasound monitoring device” (超声监控设备) — with different classification outcomes. In 2023, 23 foreign manufacturers submitted applications using the wrong catalogue code because their Chinese translation of the intended use did not match the NMPA’s terminology. Always have a native-speaking regulatory specialist review the intended use statement before submission.
Pitfall #3: Underestimating the impact of combination products. Devices that incorporate medicinal substances (e.g., drug-eluting stents, antimicrobial catheters) or biological components (e.g., collagen wound dressings) require additional classification consideration. The NMPA applies a “principal mode of action” test — if the device’s primary mechanism is pharmacological, it may be regulated as a drug (requiring NMPA’s drug approval pathway) rather than a device. In 2024, 6 combination products from foreign manufacturers were reclassified from medical devices to drugs, adding 12–18 months to their approval timelines.
Recent Classification Developments
- 2024 Catalogue Update: The 2024 revision to the Classification Catalogue added 312 new product categories, including 47 specifically for AI/ML-based medical software. AI software for diagnosis (e.g., radiology image analysis) is Class III; AI software for clinical decision support is Class II. The update also added new categories for home-use dialysis machines (Class III), wearable cardiac monitors (Class II), and telemedicine peripheral devices (Class I).
- In Vitro Diagnostic (IVD) Classification Reform (2023): The NMPA published a separate IVD Classification Catalogue with 1,200+ product entries. IVDs are classified into 3 tiers based on public health risk: Class I (basic reagents), Class II (common disease diagnostics), Class III (blood screening, genetic testing, cancer markers). Foreign IVD manufacturers face a particularly strict regime — 68% of foreign IVD products are classified as Class III under the new rules.
- Innovation Device Fast-Track (创新医疗器械特别审批程序): Since 2021, the NMPA’s “green channel” program allows certain novel devices to bypass standard classification and regulatory timelines. To qualify, the device must be (a) invented in China or have significant Chinese intellectual property, (b) address an unmet clinical need, and (c) have no equivalent on the Chinese market. 43 devices were accepted into the fast-track program in 2024, with 12 from foreign manufacturers. Fast-track devices still follow the same classification rules but receive priority review — reducing registration timelines by 30–50%.
Enforcement and Data Points
- In 2024, the NMPA’s CMDE received 6,784 new device registration applications from foreign manufacturers, of which 816 (12%) were rejected due to classification errors. This was down from 15% in 2022, indicating improving compliance as more manufacturers engage China-based regulatory consultants.
- The average cost difference between a Class II and Class III registration for a foreign manufacturer was approximately $185,000 in 2024, driven primarily by clinical trial requirements (Class III requires a full China-based clinical trial, Class II requires only a clinical evaluation report).
- The NMPA’s classification determination service processed 187 requests from foreign manufacturers in 2024, with an average processing time of 38 working days. The service is currently available in Chinese only, though English-language templates are under development.
- Since 2023, the NMPA has been harmonizing classification categories with the IMDRF (International Medical Device Regulators Forum) framework. To date, 73% of China’s classification categories now map directly to IMDRF codes, up from 61% in 2022.
Remote China market entry support, built around execution.
